What is eloralintide? What it does, benefits and what the evidence shows

Eloralintide (Eli Lilly's code name LY3841136) is an experimental injectable that activates the amylin receptor, the same hormone system that cagrilintide targets, and it is being developed for obesity. It is not approved, and DailyMed had no eloralintide label when we searched on September 28, 2026. The evidence is a lot better than "early-stage" suggests, though: a 263-person Phase 2 trial was published in The Lancet in 2025 with average weight loss of up to about 20%, and Lilly's Phase 3 program began enrolling in December 2025. What is missing is any Phase 3 result and any long-term safety data.

What eloralintide is and how it works

Eloralintide is a lab-made, long-acting drug that mimics the hormone amylin, and Lilly describes it as "selective" for the amylin receptor. Lilly says the drug has the potential to decrease calorie intake, with effects likely mediated by satiety, the feeling of fullness (Lilly, November 6, 2025 announcement).

The "selective" part is the pitch. In Lilly-authored lab work, eloralintide preferentially activated one amylin receptor subtype in human cells, and in rats it caused significantly less conditioned taste avoidance (a stand-in for nausea) than cagrilintide, which the paper describes as a non-selective amylin agonist. In obese rats it reduced food intake and body weight, mostly through loss of fat mass (Molecular Metabolism, 2025). Those are animal and cell results funded by the developer. They explain why Lilly is interested, and they are not evidence that it is gentler on people. Our cagrilintide guide covers the older, better-studied drug in the same class.

Lilly presents it as a potential alternative to incretin therapies (the GLP-1 class that includes semaglutide and tirzepatide) and as a possible complement for people who need more weight loss than those give. Whether it can do either is what the Phase 3 program is testing.

What people use it for

What the research actually shows

Weight loss in the Phase 2 trial

The Phase 2 trial enrolled 263 adults across 46 U.S. research centers. Everyone had obesity, or overweight with at least one weight-related condition, and no type 2 diabetes. Participants were randomized to placebo or to one of six eloralintide regimens: four fixed doses and two schedules that stepped the dose up over time. The main measure was percent change in body weight at the end of the treatment period, about a year in (The Lancet, 2025).

Using the efficacy estimand, which describes what happens if everyone stays on the drug, all groups beat placebo. Average weight loss ranged from 9.5% on the lowest dose to 20.1% on the highest, versus 0.4% on placebo. The two dose-escalation regimens landed at 19.9% and 16.4% (Lilly, November 6, 2025). Lilly funded the trial, and the release notes that these endpoints were not adjusted for multiplicity. The abstract we could open reports the efficacy estimand only, so we can't tell you what the more conservative analysis, which counts people who dropped out, would show. That matters, because the choice of method moves the numbers a lot: in a published survodutide liver trial, average weight change was -12.2% under the efficacy estimand but -8.7% under the treatment-regimen one (see our survodutide guide).

Context for the "20%" number: it comes from one trial, with 53 people on placebo and 24 to 54 people per drug group, run at U.S. sites only. The participants were mostly women (78%) and mostly White (78%). It is a strong Phase 2 signal, not a settled effect size.

The Lancet paper reports the trial as completed in August 2025, and ClinicalTrials.gov lists it as such (NCT06230523).

Other health markers

Lilly reports that eloralintide was also associated with improvements in waist circumference, blood pressure, lipid profiles, glycemic control and markers of inflammation (Lilly, 2025). We've listed that under "Human trials" because it comes from the randomized trial, but we only saw it in the sponsor's summary, not as figures we could check. Expect a lot of that to track with how much weight people lost.

Earlier human data

Before Phase 2, a 12-week Phase 1 study in 100 people with obesity or overweight tested several dose levels, with weight reductions from 2.6% to 11.3% across dose groups; the authors reported few gastrointestinal events in that setting, and decreased appetite (19%) was the most common event (Diabetes, Obesity & Metabolism, 2026). An earlier single-dose study in 48 healthy volunteers found mostly mild adverse events (Molecular Metabolism, 2025).

Phase 3 status

Phase 3 has started. As of the ClinicalTrials.gov records last updated September 22, 2026, Lilly is running a program called ENLIGHTEN with all trials recruiting: ENLIGHTEN-1 (obesity without diabetes, about 1,980 planned participants, started February 2026), ENLIGHTEN-2 (obesity with type 2 diabetes, started December 2025), ENLIGHTEN-3 (sleep apnea), ENLIGHTEN-4 (knee osteoarthritis pain) and ENLIGHTEN-6 (people whose obesity persists despite treatment with an incretin drug). The registry lists estimated primary completion dates in 2028. Separate Phase 2 studies are testing eloralintide alone or combined with tirzepatide or another Lilly drug, macupatide (NCT07215559). We found no published results from any of these.

Side effects and risks

In the Phase 2 trial the most common adverse events were nausea and fatigue. Nausea ranged from 11% to 13% in the two lowest-dose groups, similar to the 14% on placebo, but reached 64% in one of the middle-dose groups and 54% in a dose-escalation group. Fatigue rose with dose, from 0% in the lowest-dose group to 46% in the top escalation group, versus 12% on placebo (The Lancet, 2025). Lilly describes most of these events as mild to moderate and says they were less frequent with slower dose escalation (Lilly, 2025).

So "better tolerated" is a fair description of the lowest doses and of gradual schedules, and a harder sell for the doses that produced the biggest weight loss. The abstract also doesn't tell us how many people dropped out for side effects, which is the number that best shows real-world tolerability.

What nobody knows yet: safety beyond about a year, effects on heart outcomes, and how it behaves in people with kidney or liver problems (Phase 1 studies in liver impairment and renal impairment are listed as ongoing). The trials also screened participants and adjusted doses under supervision, which a vial bought online does not replicate.

Grey-market risks are the ones we can measure: whether the vial contains what the label says, how pure it is, whether the quantity matches, and endotoxin for an injectable (endotoxin in research peptides).

What the lab tests show

As of September 29, 2026, our database contains one eloralintide vial, from a lab report dated August 2026. It measured 99.86% pure and about 9% over its labeled amount. That is not a failure under our definition (empty, under 95% pure, more than 20% under label or more than 50% over). One vial from one report is not enough to say anything about a vendor or the market, and you shouldn't take it as evidence that other vials are accurate.

We don't have enough lab data on eloralintide to rank vendors for it, so the table below shows the highest-ranked vendors across all compounds right now. A vendor's overall record is a signal, not a guarantee for a compound they've never had tested:

Buying smarter

Check the eloralintide results page to see whether any vendor has a result for it, and look at how many reports sit behind any score on /vendors; the methodology page explains how ranking works. With a compound this new and this thinly tested, treat a posted COA as a claim to verify. How to read a peptide COA and fake peptide COAs show what to look for.

Testing your own vial is the strongest move: how to get a peptide tested covers identity, purity and quantity, and underdosed peptides explains why the label amount matters. If your report comes back bad, stop using that batch, tell anyone who bought from the same run, take the report to the vendor, and submit it to VendorVerify. If you have an eloralintide result of any kind, submitting it helps the next buyer more than anything else on this page can.

Comparing it with what's already approved: semaglutide and tirzepatide have full labels and long safety records. Eloralintide, like survodutide, is still in trials.

Database figures are from VendorVerify as of September 29, 2026. This isn't medical advice. Eloralintide is an investigational drug and is sold outside clinical trials for research use only.